Donald R. Dixon, serving as a director for Amprius Technologies, Inc. (NASDAQ: AMPX), has completed a substantial divestment of company equity. On June 15, 2026, the director sold 85,000 shares of Amprius common stock. The transaction resulted in a total value of $1,459,212, executed at an average price point of $17.1672 per share. This sale was facilitated indirectly through The Dixon Revocable Trust, an entity where Mr. Dixon and his spouse act as co-trustees. Following the completion of this sale, The Dixon Revocable Trust maintains a position of 359,380 shares in Amprius Technologies.
The timing of this transaction is notable given the current market trajectory of AMPX. The stock price has since retreated to $15.49, representing a decrease from the transaction price. Despite this recent dip, the stock has demonstrated significant appreciation over the past year, rising 280%. Market analysis indicates that AMPX is currently trading at a valuation that appears elevated compared to its fair value estimate, placing it on lists of overvalued equities. Furthermore, data highlights that the stock is characterized by high price volatility, a key metric for investors monitoring risk exposure.
In a related development, Mr. Dixon previously acquired 10,423 restricted stock units (RSUs) on June 12, 2026. These RSUs grant a contingent right to receive one share of common stock each, with vesting scheduled to occur on the earlier of the one-year anniversary of the grant date or the day before the next annual stockholders meeting, contingent upon Mr. Dixon’s continued service. Post-acquisition, Mr. Dixon’s direct holdings stand at 280,079 shares, inclusive of these RSUs. Additionally, he holds an indirect interest in 163,142 shares through the Donald & Elizabeth Dixon 2004 Family Partners, where he serves as a co-general partner.
Corporate performance metrics for Amprius Technologies present a mixed picture. The company reported its first-quarter 2026 earnings, revealing a net loss of $5 million, or -$0.04 per share. This result fell short of the expected loss of -$0.0278 per share. However, revenue performance exceeded forecasts, generating $28.5 million against a projected $25.32 million. This discrepancy between earnings miss and revenue beat has drawn investor attention.
Strategic developments also include a collaboration with Matternet. Amprius Technologies has announced plans to supply silicon anode lithium-ion batteries for Matternet’s M2 delivery drones. The partnership extends to developing future battery solutions, with volume production readiness targeted for early 2027. Conversely, the company faces scrutiny from short seller Manatee Research. A recent report by Manatee Research alleges exaggerated orders and disclosure irregularities. The investigation included interviews with battery experts and site visits, raising operational concerns that have intensified investor focus on Amprius Technologies.